Abstract:Cancer immunotherapy has revolutionized the treatment landscape by harnessing the power of the immune system to combat malignancies. Two of the most promising players in this field are cluster of differentiation 24 (CD24) and sialic acid-binding Ig-like lectin 10 (Siglec-10), and both of them play pivotal roles in modulating immune responses. CD24, a cell surface glycoprotein, emerges as a convincing fundamental signal transducer for therapeutic intervention, given its significant implication in the processes related to tumour progression and immunogenic evasion. Additionally, the immunomodulatory functions of Siglec-10, a prominent member within the Siglec family of immune receptors, have recently become a crucial point of interest, particularly in the context of the tumour microenvironment. Hence, the intricate interplay of both CD24 and Siglec-10 assumes a critical role in fostering tumour growth, facilitating metastasis and also orchestrating immune evasion. Recent studies have found multiple evidences supporting the therapeutic potential of targeting CD24 in cancer treatment. Siglec-10, on the other hand, exhibits immunosuppressive properties that contribute to immune tolerance within the tumour microenvironment. Therefore, we delve into the complex mechanisms through which Siglec-10 modulates immune responses and facilitates immune escape in cancer. Siglec-10 also acts as a viable target for cancer immunotherapy and presents novel avenues for the development of therapeutic interventions. Furthermore, we examine the synergy between CD24 and Siglec-10 in shaping the immunosuppressive tumour microenvironment and discuss the implications for combination therapies. Therefore, understanding the roles of CD24 and Siglec-10 in cancer immunotherapy opens exciting possibilities for the development of novel therapeutics.

Sialic acid and Siglec receptors in tumor immunity and immunotherapy

The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity

Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer

Tumor sialylation controls effective anti-cancer immunity in breast cancer

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Targeted glycan degradation potentiates the anticancer immune response in vivo

Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2

Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments

Unravelling CD24-Siglec-10 pathway: Cancer immunotherapy from basic science to clinical studies

Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Recent advances in sialic acid-based active targeting chemoimmunotherapy promoting tumor shedding: a systematic review

The intriguing roles of Siglec family members in the tumor microenvironment